Clearside Biomedical IncOn the above Weekly chart price action has corrected almost 90% since August 2021. A number of reasons now exist to be bullish , including:
1) A strong buy signal prints (not shown).
2) Regular bullish divergence .
3) Price action confirms support on past resistance.
4) Falling wedge breakout + bac
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.4692 USD
−34.35 M USD
1.66 M USD
61.02 M
About Clearside Biomedical, Inc.
Sector
Industry
CEO
George M. Lasezkay
Website
Headquarters
Alpharetta
Founded
2011
FIGI
BBG002D4D4X3
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. Its SCS microinjector enables a simple, repeatable, in-office procedure to deliver treatments directly to the macula, retina, or choroid, potentially helping to preserve and improve vision in patients with serious eye diseases. Its pipeline includes CLS-AX, an Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
CLSD LongUptrend Consolidation
SMA200 as support
OBV> OBV34
WR% Crossed -80
Entry 2.47
Stop 2
Target 4.3
Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader. I trade option to test my trading plan with sma
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of CLSD is 0.8000 USD — it has decreased by −1.13% in the past 24 hours. Watch Clearside Biomedical, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Clearside Biomedical, Inc. stocks are traded under the ticker CLSD.
CLSD stock has risen by 10.26% compared to the previous week, the month change is a −5.49% fall, over the last year Clearside Biomedical, Inc. has showed a −39.85% decrease.
We've gathered analysts' opinions on Clearside Biomedical, Inc. future price: according to them, CLSD price has a max estimate of 8.00 USD and a min estimate of 4.00 USD. Watch CLSD chart and read a more detailed Clearside Biomedical, Inc. stock forecast: see what analysts think of Clearside Biomedical, Inc. and suggest that you do with its stocks.
CLSD reached its all-time high on Oct 10, 2016 with the price of 25.0800 USD, and its all-time low was 0.5600 USD and was reached on Aug 28, 2019. View more price dynamics on CLSD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CLSD stock is 9.39% volatile and has beta coefficient of 0.72. Track Clearside Biomedical, Inc. stock price on the chart and check out the list of the most volatile stocks — is Clearside Biomedical, Inc. there?
Today Clearside Biomedical, Inc. has the market capitalization of 66.46 M, it has increased by 7.17% over the last week.
Yes, you can track Clearside Biomedical, Inc. financials in yearly and quarterly reports right on TradingView.
Clearside Biomedical, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
CLSD earnings for the last quarter are −0.10 USD per share, whereas the estimation was −0.098 USD resulting in a −2.46% surprise. The estimated earnings for the next quarter are −0.11 USD per share. See more details about Clearside Biomedical, Inc. earnings.
Clearside Biomedical, Inc. revenue for the last quarter amounts to 306.00 K USD, despite the estimated figure of 301.57 K USD. In the next quarter, revenue is expected to reach 183.86 K USD.
CLSD net income for the last quarter is −7.31 M USD, while the quarter before that showed −7.69 M USD of net income which accounts for 4.97% change. Track more Clearside Biomedical, Inc. financial stats to get the full picture.
No, CLSD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 21, 2025, the company has 32 employees. See our rating of the largest employees — is Clearside Biomedical, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Clearside Biomedical, Inc. EBITDA is −28.66 M USD, and current EBITDA margin is −1.72 K%. See more stats in Clearside Biomedical, Inc. financial statements.
Like other stocks, CLSD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Clearside Biomedical, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Clearside Biomedical, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Clearside Biomedical, Inc. stock shows the sell signal. See more of Clearside Biomedical, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.